Innovative ophthalmic technology

Article

Incorporating the LAL into your practice

It is often said that a chain is only as strong as its weakest link. A similar sentiment applies to the way in which a clinical practice adopts a new tool. Innovative ophthalmic technologies hold much promise, however, this promise is soon lost if such technologies are not implemented in a manner that compliments existing patient care standards.

The postoperative journey

The adjustment and lock-in process can take several weeks and involves a maximum of four visits to the treating physician's clinic. If this is considered alongside the requirement for all patients to wear UVblocking sunglasses at all times, it is clear that any patient who opts for this IOL must be accepting of a more time-intensive postoperative care plan. Similarly, physicians must adjust their standard approach to IOL implantation to accommodate this unique care plan.

Education is paramount

First and foremost, time must be taken to thoroughly explain the process to potential patients. Patients who opt for the LAL inevitably invest a lot of time, faith and money into the lens procedure. As a result, they need to have a full understanding of the concept that underlies the lens and its results. In my experience, patients do not have a great deal of knowledge about the existing range of solutions for cataracts and refractive error, as such, thorough patient education is essential.

In my practice, we have optical engineers and opticians who are dedicated to educating patients about different lens options. This is something that I am also involved in, but to ensure that all patients seeking IOL implantation are completely informed about all possible solutions, I find that delegating this task allows patient education to be performed with maximum efficiency. Once a patient has narrowed down his or her options, I then discuss these options with them in detail.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.